SGLT2

Assets acting on this target.

Class
Sodium-glucose cotransporter-2 inhibitor

Sodium-glucose cotransporter-2 (SGLT2) is a membrane protein located in the early proximal tubule of the kidney, where it reabsorbs the majority of glucose filtered from the blood back into the body, working alongside sodium. Under normal conditions this conserves glucose as an energy source, but in diabetes it also contributes to sustained high blood glucose by returning filtered sugar to circulation rather than allowing its excretion. Small-molecule inhibitors of SGLT2 block this reabsorption, causing excess glucose to be excreted in urine and thereby lowering blood glucose independent of insulin secretion or action. Because the transporter also reabsorbs sodium, its inhibition produces mild diuretic and natriuretic (sodium-excreting) effects, which lower blood pressure and reduce fluid overload. These combined glucose-lowering and fluid-modulating actions have made this mechanism broadly relevant not only in type 2 diabetes but also in chronic kidney disease and heart failure, conditions in which excess fluid retention and metabolic strain on the heart and kidneys are central problems. The insulin-independent mode of action is a key rationale for its use across a range of glycemic control needs and comorbidities, distinguishing it from older diabetes therapies that rely on stimulating or sensitizing insulin pathways.

By indication

Related mechanisms

SGLT2 drugs compared

11 drugs, stage by indication
11 drugs acting on SGLT2: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
BexagliflozinBrenzavvyNewsoara Biopharma, Theracossmall moleculeApprovedApproved in Type 2 Diabetes
CanagliflozinInvokanaDaiichi Sankyo, Johnson & Johnson, Tanabe Pharma Corporationsmall moleculeApprovedApproved in Chronic Kidney Disease; Approved in Type 2 Diabetes
DapagliflozinFarxiga / ForxigaAstraZeneca, Ono Pharmaceuticalsmall moleculeApprovedApproved in Chronic Kidney Disease; Approved in Heart Failure; Approved in Type 2 Diabetes; Phase 3 in Atherosclerotic Cardiovascular Disease
EmpagliflozinJardianceBoehringer Ingelheim, Eli Lillysmall moleculeApprovedApproved in Atherosclerotic Cardiovascular Disease; Approved in Chronic Kidney Disease; Approved in Heart Failure; Approved in Type 2 Diabetes
ErtugliflozinSteglatroMerck & Co., Pfizersmall moleculeApprovedApproved in Type 2 Diabetes
EnavogliflozinEnvloArcera Life Sciences, Daewoong Pharmaceuticalsmall moleculePhase 3Phase 3 in Chronic Kidney Disease; Phase 3 in Type 2 Diabetes
janagliflozinHuiyoujingHangzhou Zhongmei Huadong Pharmaceutical, Jilin Huisheng Biopharmaceutical, Sihuan Pharmaceutical Holdingssmall moleculePhase 3Phase 3 in Type 2 Diabetes
Zibotentan + DapagliflozinAstraZenecasmall molecule (combination)Phase 3Phase 3 in Chronic Kidney Disease
DA-2811Dong-A STsmall moleculePhase 2Phase 2 in Type 2 Diabetes
TofogliflozinApleway / DeberzaChugai Pharma, Kowa Company, Ltd.small moleculePhase 2Phase 2 in Type 2 Diabetes
OlorigliflozinSunshine Lake Pharmasmall moleculePhase 1Phase 1 in Type 2 Diabetes

← all mechanisms